1 month Syndax Pharmaceuticals (NASDAQ:SNDX) Coverage Initiated by Analysts at UBS GroupMarketBeat
UBS Group started coverage on shares of Syndax Pharmaceuticals in a research report on Thursday. They issued a “buy” rating and a $37.00 target price on the stock.
Nasdaq 100 · Pharmaceuticals · Science
X